0
Special Feature |

Picture of the Month FREE

[+] Author Affiliations

Section Editor: Walter W. Tunnessen, MD

More Author Information
Arch Pediatr Adolesc Med. 2000;154(7):746. doi:.
Text Size: A A A
Published online

DENOUEMENT AND DISCUSSION: AUTOIMMUNE POLYGLANDULAR SYNDROME TYPE 1

Figure 1. Patches of vitiligo are present in the inner canthal areas bilaterally. Generalized hyperpigmentation of the skin makes these areas more prominent.

Figure 2. The mottled appearance of the teeth reflects enamel hypoplasia.

Figure 3. The nails show signs of dystrophy, vertical ridging, and pitting.

Autoimmune polyglandular syndrome type 1 (APS-1), also known as polyendocrinopathy-candidiasis-ectodermal dystrophy, is an autosomal recessive disorder characterized by the triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency.1 A patient must have 2 of 3 major disease components for diagnosis. Other associated disorders include autoimmune endocrinopathies, immune-mediated gastrointestinal diseases, ectodermal dysplasia, keratoconjunctivitis, autoimmune skin disorders, asplenia, and cholelithiasis.

The syndrome's first manifestation typically occurs in childhood with the 3 major disease components seen by age 20 years, while associated disorders continue to appear throughout life.1,2 In most cases, candidiasis appears first, usually by age 3 years. Mucocutaneous candidiasis is the clinical expression of a selective T lymphocyte dysfunction affecting the nails, skin, esophagus, or vagina. B-cell response of serum antibodies to candidal antigens is normal and prevents systemic candidiasis development.3 Mucocutaneous candidiasis is typically mild and responds well to topical antifungal treatment or systemic drugs such as fluconazole.

ENDOCRINOPATHIES

Hypoparathyroidism, the most common autoimmune endocrinopathy associated with this syndrome, is usually the second disease to appear.2 Hypoparathyroidism results in hypocalcemia, hyperphosphatemia, and occasionally, hypomagnesemia, and has symptoms of neuromuscular irritability such as cramping and tetany of the extremities. Hypocalcemic tetany or seizures may be seen by the neonatal period. Addison disease, secondary to the autoimmune destruction of the adrenal gland, is usually the third disease to appear (mean age of onset, 13 years).1 Adrenal cortex autoantibodies may be detected before Addison disease onset. Symptoms and signs of adrenal insufficiency include weakness, fatigue, anorexia, weight loss, hyperpigmentation, and hypotension.

Other autoimmune disorders may appear. Gonadal failure is more common in females and is associated with lymphocytic infiltration of developing ovarian follicles.1 Clinical presentation ranges from delayed adolescent puberty to premature adult menopause. When other autoimmune endocrine diseases develop, such as insulin-dependent diabetes mellitus or Hashimoto thyroiditis, associated autoantibodies are typically present. Antibodies may be present without clinical manifestations of the corresponding disease.1

OTHER ASSOCIATED AUTOIMMUNE DISORDERS

Gastrointestinal disease may manifest as pernicious anemia, atrophic gastritis, cholelithiasis, malabsorption, or chronic active hepatitis, a major cause of mortality in this disease that may be present without obvious signs of liver disease.2 Autoimmune destruction of the spleen may occur and can be screened by looking for characteristic erythrocyte abnormalities on peripheral blood smears associated with asplenia: marked variation in size and shape of erythrocytes, Howell-Jolly bodies, and Heinz bodies.4 Asplenia results in increased susceptibility to bacterial infections, particularly those with capsules such as Streptococcus pneumoniae and Haemophilus influenzae. Patients with asplenia younger than 20 years are particularly susceptible to overwhelming sepsis.

Approximately 75% of individuals with APS-1 have ectodermal dystrophy.2 Clinical manifestations include pitting of the nails and dental enamel hypoplasia. These changes may occur independently of hypoparathyroidism or candidal infections. Keratopathy (corneal opacities and conjunctival injection) and calcified plaques of the tympanic membrane may also occur. Manifestations of autoimmune disorders of the skin, such as alopecia areata and vitiligo, may appear.

Autoimmune polyglandular syndrome type 1 is a rare disorder, but it is more common in certain populations, with a disease prevalence of 1:25,000 in Finland and 1:9000 in Iranian Jews.5,6 It is the only known autoimmune disease inherited in a Mendelian fashion. The gene responsible for the syndrome was recently identified on chromosome 21.7 This recent discovery should provide insight into the pathogenesis of APS-1 as well as autoimmune diseases in general. The clinical spectrum of APS-1 is broad. All patients need lifelong follow-up for the detection of new disease components, some of which may be life-threatening.

Accepted for publication March 31, 1999.

Reprints: Karen K. Winer, MD, DEB/NICHD/NIH, Bldg 10, Room 10N262, 10 Center Dr, MSC1862, Bethesda, MD 20892-1862.

Betterle  CGreggio  NAVolpato  M Autoimmune polyglandular syndrome type I. J Clin Endocrinol Metab. 1998;831049- 1055
Ahonen  PMyllarniemi  SSipila  IPerheentupa  J Clinical variation of autoimmune poly-endocfinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;3221829- 1836
Peterson  PPerheentupa  JKrohn  KJE Detection of candidal antigens in autoimmune polyglandular syndrome type I. Clin Diagn Lab Immunol. 1996;3290- 294
Friedman  TCThomas  PMFleisher  TA  et al.  Frequent occurrence of asplenism and cholelithiasis in patients with autoimmune polyglandular disease type I. Am J Med. 1991;91625- 630
Nagamine  KPeterson  PScott  HS  et al.  Positional cloning of the APCED gene. Nat Genet. 1997;17393- 398
Zlotogora  JShapiro  MS Polyglandular autoimmune syndrome type 1 among Iranian Jews. J Med Genet. 1992;29824- 826
Aaltonen  JBjorses  PSandkuijl  LPerheentupa  JPeltonen  L An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet. 1994;883- 87

Tables

References

Betterle  CGreggio  NAVolpato  M Autoimmune polyglandular syndrome type I. J Clin Endocrinol Metab. 1998;831049- 1055
Ahonen  PMyllarniemi  SSipila  IPerheentupa  J Clinical variation of autoimmune poly-endocfinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;3221829- 1836
Peterson  PPerheentupa  JKrohn  KJE Detection of candidal antigens in autoimmune polyglandular syndrome type I. Clin Diagn Lab Immunol. 1996;3290- 294
Friedman  TCThomas  PMFleisher  TA  et al.  Frequent occurrence of asplenism and cholelithiasis in patients with autoimmune polyglandular disease type I. Am J Med. 1991;91625- 630
Nagamine  KPeterson  PScott  HS  et al.  Positional cloning of the APCED gene. Nat Genet. 1997;17393- 398
Zlotogora  JShapiro  MS Polyglandular autoimmune syndrome type 1 among Iranian Jews. J Med Genet. 1992;29824- 826
Aaltonen  JBjorses  PSandkuijl  LPerheentupa  JPeltonen  L An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet. 1994;883- 87

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles